Overview

Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy.

Status:
Completed
Trial end date:
2018-10-23
Target enrollment:
Participant gender:
Summary
Clinical trial of "line extension" of drug ARAFARMADOL® 0.075% cream in a new formulation in topical solution applicable in roll-on and with the same therapeutic indications approved for the cream.
Phase:
Phase 3
Details
Lead Sponsor:
Arafarma Group, S.A.
Collaborator:
Fundación Teófilo Hernando, Spain
Treatments:
Capsaicin